ABY-071

N/A

Report date: 2026/05/14 20:00:28

NME

Base Information

Drug NameABY-071

Drug Alias NameN/A

ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionCD276 antigen modulators

TargetsCD276 antigen

Therapy Area/IndicationsTriple Negative Breast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySweden

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAffibody Medical AB

China Registration ClassN/A

Develop Information

Active CompaniesAffibody Medical AB

Inactive CompaniesN/A

Active IndicationsTriple Negative Breast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A